Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
prostate cancer
Biotech
MacroGenics pauses work on ADC pending mature survival data
MacroGenics has paused investment in additional opportunities for the ADC until it has updated data from a phase 2 monotherapy prostate cancer trial.
Nick Paul Taylor
Nov 6, 2024 4:44am
Essa drops lead cancer drug after falling short against Xtandi
Nov 1, 2024 7:33am
Prostate cancer study finds equal gains in IMRT vs. proton beam
Sep 30, 2024 10:00am
Merck inks $1.6B-plus exclusive licensing pact with Orion
Jul 1, 2024 10:38am
Prostate cancer? Ptooey! Saliva test detects aggressive tumors
Jun 3, 2024 1:30pm
ASCO: J&J's radioligand spurs responses, but 4 deaths mar data
May 24, 2024 10:51am
